Trial Profile
Investigator-initiated multi-institutional clinical trial of combination therapy of vaccination and gene-modified T cell targeting NY-ESO-1-antigen for refractory soft tissue sarcoma
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Mipetresgene autoleucel (Primary) ; Mipetresgene autoleucel (Primary) ; NY ESO 1 TCR Kite Pharma (Primary) ; NY ESO 1 TCR Kite Pharma (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TriCombo study
- 10 Dec 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 03 Mar 2021 Planned End Date changed from 28 Feb 2021 to 31 Dec 2021.
- 03 Dec 2019 Status changed from recruiting to suspended.